Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.
The protein binding of diazepam (D) and its major active metabolite N-desmethyl diazepam (DD) was investigated in vitro in the serum of 14 mothers at birth, 21 foetuses at birth, in 100 neonates between 1 and 11 days of age and in 16 control subjects. The free (unbound) fractions of D and DD in the foetus were similar to those in the controls, but lower than those in the mothers. During the first day of life the free fractions of D and DD doubled in the neonates and subsequently declined slowly to reach near control levels at 1 week of age. The sharp increase and slow decrease of the free fractions of D and DD during the first postnatal week was closely paralleled by sharply increasing and decreasing free fatty acid (FFA) concentrations. Bilirubin and albumin levels were of lower importance in regard to the protein binding of D and DD. These results indicate that the greatly increased FFA levels shortly after birth result in increased free fractions of D and DD. Because of the known immaturity of the neonatal hepatic elimination capacity, these elevated free fractions may result in elevated free concentrations of the two compounds, which may help to explain the adverse effects observed clinically in some D-exposed neonates.
D000328:Adult; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism*; D003975:Diazepam / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D003708:Nordazepam / Q000097:blood; D011247:Pregnancy; D011485:Protein Binding; D012709:Serum Albumin
D001798:Blood Proteins; D005230:Fatty Acids, Nonesterified; D012709:Serum Albumin; D003708:Nordazepam; D003975:Diazepam; D001663:Bilirubin